Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALPG | P10696 | 1/20 | 0.36 |
| ▸ | DNM2 | P50570 | 2/20 | 0.35 |
| ▸ | IDH2 | P48735 | 1/20 | 0.35 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.35 |
| ▸ | NCF1 | P14598 | 2/20 | 0.35 |
| ▸ | TOP2A | P11388 | 1/20 | 0.35 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.34 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2067802 | 0.81 | KDM6B (0.36) | CYP2C19KDM4E | |
| SCHEMBL2067361 | 0.77 | — | — | |
| SCHEMBL6032869 | 0.77 | CYP2C19 (0.50) | CYP2C19HRH3GAAALPGDNM2 | |
| SCHEMBL2067765 | 0.73 | KDM6B (0.37) | — | |
| SCHEMBL3707096 | 0.71 | CYP2C19 (0.41) | CYP2C19HRH3GAAALPGMALT1 | |
| SCHEMBL10818179 | 0.70 | CA12 (0.41) | CYP2C19GAAMEN1KMT2AKDM4E | |
| SCHEMBL18066566 | 0.70 | HRH3 (0.47) | CYP2C19HRH3GAAALPGDNM2 | |
| SCHEMBL2033568 | 0.69 | CYP2C19 (0.42) | CYP2C19HRH3GAAALPGMALT1 | |
| SCHEMBL27680514 | 0.69 | — | — | |
| SCHEMBL11454686 | 0.69 | HRH3 (0.46) | CYP2C19HRH3DNM2IDH2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296732-B2 | Substituted benzamides and their uses | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150329503-A1 | SUBSTITUTED BENZAMIDES AND THEIR USES | UNIV LELAND STANFORD JUNIOR (US) | 2015-11-19 | — | — | US | disclosed |
| US-9085570-B2 | Substituted benzamides and their uses | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-07-21 | — | — | US | disclosed |
| US-20150072976-A1 | SUBSTITUTED BENZAMIDES AND THEIR USES | ARAVIVE BIOLOGICS, INC. | 2015-03-12 | — | — | US | disclosed |
| US-20140024649-A1 | Substituted Benzamides and Their Uses | AUCKLAND UNISERVICES LIMITED (NZ) | 2014-01-23 | — | — | US | disclosed |
| EP-2627324-A2 | SUBSTITUTED BENZAMIDES AND THEIR USES | The Board of Trustees of The Leland Stanford Junior University (US) | 2013-08-21 | — | — | EP | disclosed |
| WO-2012051117-A2 | SUBSTITUTED BENZAMIDES AND THEIR USES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329503-A1 | SUBSTITUTED BENZAMIDES AND THEIR USES | NISCH, BTD, NAAA | CYP2C19 190/4885HRH3 780/4885GAA 138/4885 |
| US-20140024649-A1 | Substituted Benzamides and Their Uses | NISCH, BTD, NAAA | CYP2C19 190/4885HRH3 780/4885GAA 138/4885 |
| US-20150072976-A1 | SUBSTITUTED BENZAMIDES AND THEIR USES | NISCH, BTD, NAAA | CYP2C19 190/4885HRH3 780/4885GAA 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.